radiomics.bio Welcomes Jan Groen as Chairman

Liège, Belgium, – 08:00 CET, 10 March 2025 – radiomics.bio (OncoRadiomics SA)., a leading AI-powered medical imaging clinical research organization (CRO) based in Belgium’s LégiaPark business center, has announced the appointment of Dr. Jan Groen as the new chairman of the board of directors succeeding Dr. Michel Baijot. 

Having served as Board Chairman since 2018, Michel has contributed immeasurably to the growth of radiomics.bio and has successfully guided the company through multiple phases.
radiomics.bio is delighted to announce that as of the General Assembly decision of the 28th of February, Dr. Jan Groen will take over as Board Chairman. This transition marks a new chapter in the company’s journey as it continues its mission to optimize drug development through advanced AI-powered medical imaging. 
Jan Groen has over twenty-five years of experience in the clinical precision diagnostics and biotech industry, which provides critical market insight as radiomics.bio drives forward its commercial pharma service roll-out. He is also a recognized expert in biomarker discovery, cancer genetics and molecular diagnostics having earned multiple awards, holding several patents and having published over 125 scientific publications. Furthermore, Jan has vast experience in guiding successful life science ventures by increasing shareholder value and helping EU companies expand into the US market. 

“We are incredibly grateful for the contributions Michel has made within the company over the last few years, especially during pivotal moments in the company’s development. We wish him the best in his new endeavors,”stated Wim Vos, Chief Executive Officer of radiomics.bio. “Also, we are pleased to have Jan on board who brings undeniable experience with the specific knowledge that will truly allow us as a company to break barriers into other markets.”

“I am excited to lead the board and work with my fellow board members, between the expertise, knowledge and experience of not only the board but also internally on the radiomics.bio team, there is a great window of opportunity for us to expand into something great, building on what has already been achieved and make significant advancements in drug development,”stated Dr. Jan Groen. 

“We have seen quite a few changes in the company’s structure as of late, we are looking forward to seeing the fruits that it will produce, our gratitude remains with those both past and present that have allowed radiomics.bio to solidify its position in the optimization of drug development and will allow the company to continue to flourish,”stated Leen Limbourg MD, representative of Noshaq Group, radiomics.bio’s primary investor. 

About radiomics.bio: 
radiomics.bio is an AI-powered medical imaging and advanced statistics clinical research organization, optimizing the development of new oncology treatments. radiomics.bio supports biotech and pharma companies in all stages of clinical development offering services including disease characterization, dose impact quantification, response evaluation, image biomarker identification and outcome predictions. With radiomics.bio you can quantify response for objective decision making, obtain early insights from clinical trials, explore and validate drug mechanisms of action, and increase your understanding of disease on a patient, organ, or lesion level for insight-based decision making. For more information visit www.radiomics.bio.

A warm farewell and new beginnings, Mathieu Delveaux passes the baton to newly appointed CFO, Paul Mauhin

Liège, Belgium, 10/01/2025 – Paul Mauhin joins the radiomics.bio team as Chief Financial Officer as Mathieu Delveaux steps down after 5 fruitful years to further develop other promising ventures and continue his entrepreneurial journey at Altesia.  

“It has been a pleasure to accompany the company from a start up to the scale-up that it is today. As I continue to follow radiomics.bio but this time from afar, I wish the team the best and look forward to seeing how they will continue to develop and make a difference in the cancer research space,” shared Mathieu Delveaux. 

Chief Executive Officer of radiomics.bio, Wim Vos stated, 

We will certainly miss Mathieu, both personally and professionally. His personality and skillset have been instrumental to achieving our current status and we are very lucky to have shared this part of the voyage with him over the last 5 years. We wish him the best in his new endeavours and have no doubt he will continue to do great things.” 

Mathieu now passes the reigns to Paul Mauhin, an accomplished financial executive with extensive expertise in both the biotech and industrial technology sectors. Holding a master’s degree from HEC Liège, he brings a robust background in financial management and strategic operations, consistently demonstrated by his leadership in guiding companies through critical growth phases.   

The newly appointed CFO shared, “Firstly, I’d like to extend my gratitude to the team at radiomics.bio for their warm welcome and particularly to Mathieu who created an ideal environment for a seamless transition. I am very excited to join radiomics.bio as the company propels into a new chapter and I am very much looking forward to playing a part in the success story of radiomics.bio.”  

About radiomics.bio:
radiomics.bio is an AI-powered medical imaging and advanced statistics clinical research organisation, optimising the development of new oncology treatments.